A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
Hidetoshi Hayashi(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Yuichi Ozawa(Wakayama Medical University), Motoko Tachihara(Kobe University), Yasutaka Chiba(Kindai University Hospital), Kazuko Sakai(Kindai University Sakai Hospital), Nobuyuki Yamamoto(Wakayama Medical University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Satoru Miura(Niigata Cancer Center Hospital), Koichi Azuma(Kyushu University Hospital), Keiichi Ota(Dana-Farber Cancer Institute), Shinobu Hosokawa(Okayama Red Cross General Hospital), Shota Omori(Shizuoka Cancer Center), Koji Haratani(Dana-Farber Cancer Institute), Yuki Sato(Goethe University Frankfurt), Junko Tanizaki(Kindai University Sakai Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Satoshi Hara(Itami City Hospital), Yasushi Fukuda(Kurashiki Central Hospital), Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k